Patent intelligence · US
US 8507195
MiRNAs dysregulated in triple-negative breast cancer
MiRNAs dysregulated in triple-negative breast cancer
Patent details — US 8507195
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 13, 2013
- Expiration
- Aug 8, 2033
- Claims
- 14
- CPC classes
- A61P, A61P35/00
Quick answer
US 8507195 (MiRNAs dysregulated in triple-negative breast cancer) is held by The Regents of the University of Colorado. Status: granted. Granted Aug 13, 2013. Expires Aug 8, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 14
- CPC classes
- A61P, A61P35/00
More from The Regents of the University of Colorado
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 8507195?
US 8507195 (MiRNAs dysregulated in triple-negative breast cancer) is held by The Regents of the University of Colorado. Status: granted. Granted Aug 13, 2013. Expires Aug 8, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8507195?
The Regents of the University of Colorado is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 8507195 expire?
Our index shows an expiration date of Aug 8, 2033 (7 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.